λ-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C

Hepatology Research

Volumn 40, Issue 5, 2010, Pages 449-460

  Tanaka, Yasuhito ^a   Nishida, Nao ^b   Sugiyama, Masaya ^a   Tokunaga, Katsushi ^b   Mizokami, Masashi ^a,c  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c 1 7 1 Kohnodai   (Japan)

Author keywords

IL28B; Interferon lambda; Pegylated interferon; Polymorphism; Ribavirin

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERFERON; INTERFERON LAMBDA2; INTERFERON LAMBDA3; INTERLEUKIN 10 RECEPTOR 2; INTERLEUKIN 28 RECEPTOR 1; INTERLEUKIN 28A; INTERLEUKIN 28B; INTERLEUKIN 29; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CHROMOSOME 19; ENCEPHALOMYOCARDITIS VIRUS; GENE EXPRESSION; GENE STRUCTURE; GENETIC ASSOCIATION; GENOME; HANTAVIRUS; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLUENZA VIRUS A; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 77954368611     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00671.x     Document Type: Review

References (46)

1. Ray Kim W. Global epidemiology and burden of hepatitis C. Microbes Infect 2002, 4:1219-25.
2. Manns MP, McHutchison JG, Gordon SC. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-65.
3. Fried MW, Shiffman ML, Reddy KR. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-82.
4. Hadziyannis SJ, Sette H, Morgan TR. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-55.
5. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36:S237-44.
6. Pascu M, Martus P, Hohne M. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 2004, 53:1345-51.
7. Shirakawa H, Matsumoto A, Joshita S. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008, 48:1753-60.
8. Akuta N, Suzuki F, Sezaki H. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005, 48:372-80.
9. Walsh MJ, Jonsson JR, Richardson MM. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006, 55:529-35.
10. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004, 39:880-90.
11. Matsuyama N, Mishiro S, Sugimoto M. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 2003, 25:221-5.
12. Tsukada H, Ochi H, Maekawa T. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology 2009
13. Suppiah V, Moldovan M, Ahlenstiel G. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100-4.
14. Ank N, Iversen MB, Bartholdy C. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 2008, 180:2474-85.
15. Ge D, Fellay J, Thompson AJ. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
16. Tanaka Y, Nishida N, Sugiyama M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105-9.
17. Thomas DL, Thio CL, Martin MP. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
18. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 2009, 284:20869-75.
19. Sheppard P, Kindsvogel W, Xu W. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003, 4:63-8.
20. Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol 2005, 174:1932-7.
21. Onoguchi K, Yoneyama M, Takemura A. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 2007, 282:7576-81.
22. Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol 2007, 179:3434-42.
23. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. Plos Pathog 2008, 4:e1000017.
24. Zhou L, Wang X, Wang YJ. Activation of toll-like receptor-3 induces interferon-lambda expression in human neuronal cells. Neuroscience 2009, 159:629-37.
25. Jaitin DA, Roisman LC, Jaks E. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol 2006, 26:1888-97.
26. Jaks E, Gavutis M, Uze G, Martal J, Piehler J. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 2007, 366:525-39.
27. Kotenko SV, Gallagher G, Baurin VV. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003, 4:69-77.
28. Mordstein M, Kochs G, Dumoutier L. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. Plos Pathog 2008, 4:e1000151.
29. Witte K, Gruetz G, Volk HD. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009, 10:702-14.
30. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol 2004, 76:314-21.
31. Hikami K, Ehara Y, Hasegawa M. Association of IL-10 receptor 2 (IL10RB) SNP with systemic sclerosis. Biochem Biophys Res Commun 2008, 373:403-7.
32. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004, 279:32269-74.
33. Hou W, Wang X, Ye L. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol 2009, 83:3834-42.
34. Serra C, Biolchini A, Mei A, Kotenko S, Dolei A. Type III and I interferons increase HIV uptake and replication in human cells that overexpress CD4, CCR5, and CXCR4. AIDS Res Hum Retroviruses 2008, 24:173-80.
35. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006, 80:4501-9.
36. Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun 2009, 10:125-31.
37. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 2005, 31:109-18.
38. Stoltz M, Ahlm C. Lundkvist A and Klingstrom J. Lambda interferon (IFN-lambda) in serum is decreased in hantavirus-infected patients, and in vitro-established infection is insensitive to treatment with all IFNs and inhibits IFN-gamma-induced nitric oxide production. J Virol 2007, 81:8685-91.
39. Wang J, Oberley-Deegan R, Wang S. Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda 1) in response to influenza A infection. J Immunol 2009, 182:1296-304.
40. Osterlund P, Veckman V, Siren J. Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J Virol 2005, 79:9608-17.
41. Hong SH, Cho O, Kim K, Shin HJ, Kotenko SV, Park S. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res 2007, 126:245-9.
42. Doyle SE, Schreckhise H, Khuu-Duong K. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006, 44:896-906.
43. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005, 79:3851-4.
44. Marcello T, Grakoui A, Barba-Spaeth G. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 131:1887-98.
45. Zhu H, Butera M, Nelson DR, Liu C. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J 2005, 2:80.
46. Brand S, Zitzmann K, Dambacher J. SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem Biophys Res Commun 2005, 331:543-8.